Investigation launched into Abeona Therapeutics over possible securities fraud after Q2 revenue report.

Pomerantz LLP is investigating Abeona Therapeutics and some of its officers for potential securities fraud following the company's Q2 2026 financial report. Abeona disclosed that only four out of five treatments for its therapy ZEVASKYN were recognized for revenue, causing its stock to drop nearly 15% on August 13, 2026. The investigation aims to determine if Abeona engaged in unlawful business practices. Investors affected are encouraged to contact Pomerantz LLP to join the class action.

As of Sep 17, 2026 21:15 WIB, Abeona Therapeutics Inc (ABEO) trades at USD 5.40 on Pluang, showing a modest 0.56% increase in the last day. The stock's market cap stands at $307.94 million, with a trading volume of 1,902,569 shares and an enterprise value of $180.98 million. Despite recent legal scrutiny, the typical hold time for ABEO on Pluang is 22 days, indicating a relatively short-term investor interest. The most notable figure is the market cap of $307.94 million, reflecting the company's valuation on the platform.